Sanofi’s Lemtrada Wins U.S. Approval to Treat MS
This article is for subscribers only.
Sanofi won U.S. approval for Lemtrada to treat multiple sclerosis, helping ease the company’s potential revenue loss from its top-selling diabetes drug Lantus that is expected to face competition next year.
The Food and Drug Administration cleared the drug for patients with multiple sclerosis defined by periods of relapse and remission, the most common form of the disease, Sanofi said yesterday in a statement. The FDA denied Sanofi’s request to sell Lemtrada in December and said clinical trials on the drug weren’t adequate.